1. Home
  2. SLVM vs TNDM Comparison

SLVM vs TNDM Comparison

Compare SLVM & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

N/A

Current Price

$36.17

Market Cap

1.7B

ML Signal

N/A

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$19.93

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
TNDM
Founded
1898
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
SLVM
TNDM
Price
$36.17
$19.93
Analyst Decision
Strong Buy
Buy
Analyst Count
3
19
Target Price
$54.00
$28.00
AVG Volume (30 Days)
223.8K
1.7M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
4.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,351,000,000.00
$1,014,736,000.00
Revenue This Year
$0.93
$8.11
Revenue Next Year
$1.54
$11.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.93
52 Week Low
$34.25
$11.46
52 Week High
$56.80
$29.65

Technical Indicators

Market Signals
Indicator
SLVM
TNDM
Relative Strength Index (RSI) 39.93 44.89
Support Level N/A $19.70
Resistance Level $40.13 $20.79
Average True Range (ATR) 1.18 1.14
MACD -0.18 -0.44
Stochastic Oscillator 28.61 4.39

Price Performance

Historical Comparison
SLVM
TNDM

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: